News
Check out the posts below to learn the latest updates on our progress
- April 8 2022Generation of tertiary lymphoid structures and CD3pos CD8pos CD56pos NKG2Dpos CAR TaNK cells following subcutaneous injection of CD3-directed lentiviral vector-loaded PBMC
AACR 2022 - March 15 2022EXUMA Biotech to Present Preclinical Data from its Subcutaneous CAR-TaNK and In Vivo CAR Cell and Gene Therapy Programs at the American Association for Cancer Research Annual MeetingPRNewswire
- December 21 2021EXUMA Biotech Completes Series B2 to Advance Novel Cell & Gene TherapiesPRNewswire
- September 22 2021EXUMA Biotech to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare ConferencePRNewswire
- August 2 2021Building Scientific Trust Virtually
Life Science Leader - April 9 2021Subcutaneous injection of total nucleated cells rapidly isolated following four-hour peripheral whole blood exposure to CD3-directed CAR-T lentiviruses with a synthetic driver results in robust CAR-T proliferation and anti-tumor immunity
AACR Annual Meeting 2021 - February 16 2021EXUMA Biotech on NPR’s TechNation with Dr. Moira Gunn
TechNation Radio - February 5 2021Economically Viable, Same-Day Autologous Cell Therapies
Pharma's almanac - January 11 2021EXUMA Biotech Announces Collaboration with Moffitt Cancer Center for the Development of a Rapid-Point-Of-Care SC CAR-T ProgramPRNewswire
- November 11 2020EXUMA Biotech Presents Preclinical Data on Rapid Point-of-Care “rPOC” Subcutaneous CAR-T Platform at the SITC 35th Anniversary Annual Meeting & Pre-Conference
PR Newswire